Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Organ perforation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Organ perforation. Displaying page 1 of 1.
    EudraCT Number: 2007-002121-80 Sponsor Protocol Number: 47/2007/O/Sper Start Date*: 2007-09-25
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A prospective, double-blind, multi center, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin- Sulbactam 3 days in the treatment of localized communi...
    Medical condition: localized community acquired intra-abdominal infection (IAI)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10017967 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005604-54 Sponsor Protocol Number: NXL104/2002 Start Date*: 2009-04-10
    Sponsor Name:Novexel, S.A.
    Full Title: A prospective, multicentre, double-blind, randomized, comparative study to estimate the safety, tolerability and efficacy of NXL104/ceftazidime plus metronidazole vs. meropenem in the treatment of ...
    Medical condition: Complicated intra-abdominal infections (cIAI) in hospitalised adults
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021881 Infections and infestations SOC
    9.1 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003773-34 Sponsor Protocol Number: IT001-303 Start Date*: 2018-11-23
    Sponsor Name:Iterum Therapeutics International Limited
    Full Title: A prospective Phase 3, double-blind, multicenter, randomized study of the efficacy and safety of sulopenem followed by sulopenem etzadroxil with probenecid versus ertapenem followed by ciprofloxaci...
    Medical condition: Complicated intra-abdominal infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) BG (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-006056-37 Sponsor Protocol Number: 1160.143 Start Date*: 2013-09-05
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardi...
    Medical condition: MINS (myocardial injury after noncardiac surgery)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10066592 Post procedural myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) PT (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-002726-39 Sponsor Protocol Number: D4910C00009/C3601001 Start Date*: 2016-02-25
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abd...
    Medical condition: Complicated Intra-Abdominal Infections (cIAIs) in hospitalized adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001086-41 Sponsor Protocol Number: UKM10_0014 Start Date*: 2012-02-28
    Sponsor Name:University Hospital of Muenster
    Full Title: A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an in...
    Medical condition: untreated acute myeloid leukemia patients unfit for an intensive treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004636-52 Sponsor Protocol Number: 2005AN005 Start Date*: 2006-02-20
    Sponsor Name:Heart of England NHS Foundation Trust
    Full Title: Randomised Double-Blind Placebo Controlled Trial of 40mg/day of Atorvastatin on Reduction in Severity of Sepsis in Ward Patients
    Medical condition: Sepsis is the clinical syndrome defined by the presence of both infection and a systemic inflammatory response. Sepsis is common in general medical and surgical wards with an estimated prevalence ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002547-29 Sponsor Protocol Number: ATB-203 Start Date*: 2019-11-21
    Sponsor Name:Atox Bio
    Full Title: Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with ...
    Medical condition: Acute kidney injury due to intra-abdominal infection/sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10080269 Stage 2 acute kidney injury LLT
    20.1 100000004857 10080271 Stage 3 acute kidney injury LLT
    20.1 100000004862 10079983 Complicated intra-abdominal infection LLT
    20.0 100000004862 10040050 Sepsis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004800-20 Sponsor Protocol Number: MK-3475-937 Start Date*: 2019-08-22
    Sponsor Name:Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete ...
    Medical condition: Adjuvant treatment of HCC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002940-17 Sponsor Protocol Number: N16NCI Start Date*: 2016-11-25
    Sponsor Name:Antoni van Leeuwenhoek
    Full Title: Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer
    Medical condition: stage 2-3 adenocarcinoma of the colon
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009957 Colon carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000729-13 Sponsor Protocol Number: 2020_0068 Start Date*: 2021-01-21
    Sponsor Name:Hôpital Foch
    Full Title: Evaluation of Glucocorticoids plus Rituximab compared to Glucocorticoids plus Placebo for the treatment of patients with newly-diagnosed or relapsing IgA vasculitis : A prospective, randomized, con...
    Medical condition: Patients with a diagnosis of IgAV according to Chapel Hill Consensus Conference definitions. Patients will require having a biopsy-proven diagnosis of IgAV.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001162-12 Sponsor Protocol Number: EFC16844 Start Date*: 2020-03-26
    Sponsor Name:Sanofi-aventis Recherche et Développement
    Full Title: An adaptive phase 3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19
    Medical condition: Corona virus infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003402-40 Sponsor Protocol Number: XL184-401 Start Date*: 2015-06-16
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
    Medical condition: Progressive Metastatic Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) ES (Ongoing) FR (Completed) PL (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003854-17 Sponsor Protocol Number: N17PND Start Date*: 2018-02-14
    Sponsor Name:Antoni van Leeuwenhoek
    Full Title: Neoadjuvant capecitabine, oxaliplatin, docetaxel and atezolizumab in non-metastatic, resectable gastric and GE-junction cancer.
    Medical condition: GE junction cancer, gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10017768 Gastric cancer stage IV without metastases LLT
    21.1 100000004864 10066350 Adenocarcinoma of the gastrooesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005108-32 Sponsor Protocol Number: BP29262 Start Date*: 2014-08-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO5520985 (VANUCIZUMAB) PLUS FOLFOX VERSUS BEVACIZUMAB PLUS FOLFOX IN PATIENTS WITH PREVIOUSLY UNTREA...
    Medical condition: Patients with cancer of the colon or rectum where the tumor has already spread to other organs(s),
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055097 Rectal cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055114 Colon cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003895-35 Sponsor Protocol Number: D4280C00005 Start Date*: 2012-04-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole V...
    Medical condition: Complicated Intra-Abdominal Infection (cIAI)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) GR (Completed) ES (Completed) BG (Completed) IT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004364-25 Sponsor Protocol Number: GINECO-OV244b Start Date*: 2021-01-08
    Sponsor Name:ARCAGY-GINECO
    Full Title: Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI®) with or without anti-PD1 (Pembrolizumab) versus best supportive care as maintenance treatment in platinum-sensitive r...
    Medical condition: 1st or 2nd platinum-sensitive recurrent ovarian cancer with controlled disease after platinum based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 12:14:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA